Search results (92)
« Back to NewsEbola vaccine to begin human trials
11 November 2021
Clinical Trials General Research
The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.
Oxford researchers test potential treatment for fatigue in long COVID patients
29 October 2021
Clinical Trials Coronavirus COVID-19 General Research
Radcliffe Department of Medicine researcher Dr Betty Raman is leading a new phase 2a clinical trial to investigate whether a drug could treat the fatigue and muscle weakness experienced by many patients who have recovered from COVID. The drug, AXA1125, is developed by the US-based biotechnology company Axcella Therapeutics.
Anti-cancer drug derived from fungus shows promise in clinical trials
7 October 2021
Clinical Trials General Innovation Research
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
African trial of novel HIV vaccine candidate starts
4 August 2021
Clinical Trials General Research
The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) – of which the University of Oxford is a lead partner – announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.
Phase I trial begins of new vaccine against the Plague
27 July 2021
Clinical Trials General Research
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
HIV vaccine trial starts at Oxford
5 July 2021
Clinical Trials General Research
The University of Oxford today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
Clinical Trials Coronavirus COVID-19 General Research
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
Clinical Trials Coronavirus COVID-19 General Research
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial
23 June 2021
Clinical Trials Coronavirus COVID-19 General Research
From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity
18 May 2021
Clinical Trials Coronavirus COVID-19 General Research
Researchers running the University of Oxford-led Com-COV study – launched earlier this year to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine – report preliminary data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules.
Promising malaria vaccine enters final stage of clinical testing in West Africa
7 May 2021
Clinical Trials General Research
First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.
Azithromycin not effective against COVID-19, trial confirms
28 April 2021
Clinical Trials General Research
A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.
Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal
23 April 2021
Clinical Trials General Research
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.
Human challenge trial launches to study immune response to COVID-19
19 April 2021
Clinical Trials Coronavirus COVID-19 General
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Alternating vaccines trial expands to include two additional vaccines
14 April 2021
Clinical Trials Coronavirus COVID-19 General
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19
12 April 2021
Clinical Trials Coronavirus COVID-19 Research
Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.
University of Oxford to study nasal administration of COVID-19 vaccine
26 March 2021
Clinical Trials Coronavirus COVID-19 General
The University of Oxford is launching a study investigating the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray.
AstraZeneca publish primary analysis from US trial of coronavirus vaccine
25 March 2021
Clinical Trials Coronavirus COVID-19 General Research
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective
22 March 2021
Clinical Trials Coronavirus COVID-19 General Research
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine
3 March 2021
Clinical Trials Coronavirus COVID-19 General Research
From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.